Immix Biopharma's NXC-201 Hits 89% Complete Response Rate in Phase 2 NEXICART-2 AL Amyloidosis Study
核心洞察
Immix Biopharma reported an 89% complete response rate (40 of 45 patients) with NXC-201 in the Phase 2 NEXICART-2 study in relapsed/refractory AL amyloidosis (搜索).
All 25 newly evaluated patients were either in complete response (21) or already minimal residual disease-negative (4), with MRD-negativity predicting future CR.
The company said the four MRD-negative patients could lift the eventual complete response rate to as high as 98% (44 of 45), with no relapses observed to date.
Immix Biopharma reported an 89% complete response rate across all 45 patients enrolled in the Phase 2 NEXICART-2 study of NXC-201 in relapsed or refractory AL amyloidosis (搜索), according to an interim update released Sept. 29, 2026. Forty of the 45 patients achieved a complete response (CR) as assessed by an independent review committee.
The registrational-design, multicenter U.S. Phase 2 trial (NCT06097832) is planned to enroll 45 patients and evaluates NXC-201, an investigational, sterically optimized B-cell maturation antigen (BCMA (搜索))-targeted chimeric antigen receptor T-cell (CAR-T) therapy. The construct carries a proprietary CD3ζ, CD8 hinge and binder "digital filter" designed to filter out non-specific activation, and is intended to teach the immune system to recognize and eliminate the source of toxic light chains.
New Patient Cohort Fully Responding or MRD-Negative
Among the 25 newly evaluated patients, 21 achieved a complete response and the remaining four were already minimal residual disease (MRD)-negative. Immix Biopharma said all patients who have achieved MRD-negativity to date subsequently reached complete response within one year of treatment.
The company stated that the four patients currently MRD-negative could potentially convert to complete response, which would raise the overall CR rate to as high as 98%, or 44 of 45 patients. MRD-negativity in bone marrow is described as predicting future CR in these pending patients.
No relapses have been observed to date among patients who achieved complete response or MRD-negativity. The company also reported that no neurotoxicity or enterocolitis has been observed in the study.
"Today, patients with AL Amyloidosis (搜索) face years of burdensome, continuous treatment. As a potential one-and-done treatment option, NXC-201 could liberate patients from that burden," said Ilya Rachman, MD, PhD, chief executive officer of Immix Biopharma. "We are thrilled with NXC-201's magnitude of effect across a broad range of relapsed/refractory AL Amyloidosis patients in NEXICART-2."
Gabriel Morris, president of Immix Biopharma, said the complete response rate continues to increase over time even as reported patient counts have more than doubled, adding that the company looks forward to final readout, BLA submission and potentially making NXC-201 available to relapsed/refractory AL amyloidosis (搜索) patients at commercial launch.
Disease Burden and Regulatory Status
AL amyloidosis (搜索) is a rare blood disorder in which abnormal plasma cells produce toxic light-chain proteins that accumulate in organs including the heart, kidneys and liver, potentially leading to organ damage and failure. Immix Biopharma describes the disease as one in which the immune system continuously produces toxic light chains that clog the heart, kidney and liver, causing organ failure and death.
The number of patients in the U.S. with relapsed/refractory AL amyloidosis (搜索) is estimated to be growing at 12% per year, to approximately 30,506 patients in 2026, according to Staron et al. in the Blood Cancer Journal, as cited by the company. The amyloidosis market was $6.2 billion in 2025 and is expected to reach $6.6 billion in 2026, according to Grand View Research.
NXC-201 has received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration (搜索), as well as Orphan Drug Designation from the FDA and the European Medicines Agency (搜索).
Immix Biopharma plans to report final NEXICART-2 results and submit a Biologics License Application for NXC-201 in 2027, with the company specifying mid-2027 for both milestones.